Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S36-S44, March 2004

A Cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension☆

  • John G. Walt, MBA

      Affiliations

    • Corresponding Author InformationReprint address: John Walt, MBA, Global Pharmacoeconomic Strategy and Research, Allergan Inc, 2525 Dupont Drive, Irvine, CA, 92612-1599.
    • ,
  • Jeffrey T. Lee, PharmD, FCCP

Global Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ These data were presented at the Annual Meeting of Managed Care Pharmacy; October 17–20, 2001; Dallas, TX. John Walt and Jeffrey Lee are employees of Allergan, Inc.

PII: S0039-6257(03)00193-0

doi:10.1016/j.survophthal.2003.12.018

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S36-S44, March 2004

Article Tools

* Image Usage & Resolution